Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group IND.191 - A Phase II Study of AT9283 in Patients with Relapsed or Refractory Multiple Myeloma

Canadian Cancer Trials Group IND.191, a single arm phase II trial, was designed to explore the efficacy of AT9283 in patients with relapsed and refractory multiple myeloma.

Between February 2011 and July 2012, eight eligible patients were accrued and the trial was closed due to slow accrual and toxicity, in particular myelosuppression. Factors contributing to poor accrual in this trial for patients with multiple myeloma included the need for central venous catheter insertion for drug administration by 24-h infusion, a major inconvenience for patients and a resource-intensive approach for cancer treatment centers when out-patient oral or single injection subcutaneous therapy is now most commonplace. Patients considering participation in this trial would in many cases have had other active, more convenient and potentially well tolerated agents to consider as alternatives, either as standard therapy or in the context of clinical trials.

Among the eight patients enrolled, no objective responses were observed. While the limitations of this trial do not permit firm conclusions, AT9283 at this dose and schedule is not recommended for further study as a treatment for myeloma.

Hay AE, Murugesan A, DiPasquale AM, Kouroukis T, Sandhu I, Kukreti V, Bahlis NJ, Lategan J, Reece DE, Lyons JF, Sederias J, Xu H, Powers J, Seymour LK, Reiman T. A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapsed or Refractory Multiple Myeloma: Canadian Cancer Trials Group IND.191. Leuk Lymphoma 1-9, 2015.

Canadian Cancer Trials Group BR.24 - A Phase II/III Double Blind Randomized Trial of AZD2171 versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer

Addison CL, Ding K, Seymour L, Zhao H, Laurie SA, Shepherd FA, Goss GD, Bradbury PA. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the Canadian Cancer Trials Group BR.24 clinical trial. Lung Cancer 90: 288-95, 2015.

Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, Blanke CD. The Globalization of Cooperative Groups. Semin Oncol 42: 693-712, 2015.

Seymour L, Groshen S, Rosner GL, Sullivan DM, Spriggs DR, Reeves S, Gravell A, Ivy SP, Ratain MJ. Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. Clin Cancer Res 21: 5057-63, 2015.